“Spyre is entering a new chapter as we begin to explore the potential of our pipeline to reshape the treatment paradigm in chronic immune-mediated diseases,” said Cameron Turtle, CEO of Spyre. “The launch of the SKYLINE-UC platform trial and upcoming initiation of the SKYWAY-RD basket trial mark the beginning of our effort to identify products with indication-leading profiles. Between these two efficient studies, we are poised to generate nine proof-of-concept readouts in inflammatory bowel disease and rheumatic conditions over the next two years. Backed by robust science, a committed team, and a strong balance sheet with expected runway into the second half of 2028, we believe Spyre is uniquely positioned to drive meaningful and sustained value for patients and investors alike.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics: A Promising Buy in the IBD Market with Innovative Combination Biologics and Strategic Milestones
- Positive Phase 2 Data from APGE Bolsters Spyre Therapeutics’ Strategy and Stock Appeal
- Spyre Therapeutics: Strategic Execution and Promising Clinical Data Justify Buy Rating
- Promising Potential and Strategic Growth Justify Buy Rating for Spyre Therapeutics
- Buy Rating for Spyre Therapeutics: Promising Monoclonal Antibodies and Strategic Market Positioning